Meta-analysis of randomized controlled trials reveals an improved clinical outcome of using genotype plus clinical algorithm for warfarin dosing

Journal of Thrombosis and Thrombolysis

Volumn 39, Issue 2, 2015, Pages 228-234

  Liao, Zhenqi ^a   Feng, Shaoguang ^b   Ling, Peng ^a   Zhang, Guoqing ^a  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Genotype algorithm; Meta analysis; Warfarin dosing

Indexed keywords

ANTICOAGULANT AGENT; CYTOCHROME P450 2C9; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN; WARFARIN;

ALGORITHM; CLINICAL PATHWAY; DOSE RESPONSE; GENETICS; GENOTYPE; GENOTYPING TECHNIQUE; HUMAN; INTERNATIONAL NORMALIZED RATIO; META ANALYSIS; PERSONALIZED MEDICINE; PHARMACOGENETICS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS; STATISTICS AND NUMERICAL DATA; THROMBOEMBOLISM; TREATMENT OUTCOME;

ALGORITHMS; ANTICOAGULANTS; CRITICAL PATHWAYS; CYTOCHROME P-450 CYP2C9; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; INTERNATIONAL NORMALIZED RATIO; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PHARMACOGENETICS; PRECISION MEDICINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOEMBOLISM; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84932197494     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1099-9     Document Type: Article

References (29)

1. Johnson J, Gong L, Whirl-Carrillo M, Gage B, Scott S et al (2011) Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 90:625–629
2. Anderson JL, Horne BD, Stevens SM, Woller SC, Samuelson KM et al (2012) A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II) clinical perspective. Circulation 125:1997–2005
3. Wadelius M, Pirmohamed M (2006) Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 7:99–111
4. Hylek EM. Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors; 2003. Thieme Medical Publishers, pp. 271–278.
5. Hylek EM, Skates SJ, Sheehan MA, Singer DE (1996) An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335:540–546
6. Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR (2012) Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One 7:e44064
7. Yang J, Chen Y, Li X, Wei X, Chen X et al (2013) Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis. Int J Cardiol 168:4234–4243
8. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557
9. Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
10. Hillman MA, Wilke RA, Yale SH, Vidaillet HJ, Caldwell MD et al (2005) A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res 3:137–145
11. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S et al (2007) Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116:2563–2570
12. Caraco Y, Blotnick S, Muszkat M (2008) CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 83:460–470
13. Wang M, Lang X, Cui S, Fei K, Zou L et al (2012) Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: a randomized and controlled trial. Int J Med Sci 9:472–479
14. Jonas DE, Evans JP, McLeod HL, Brode S, Lange LA et al (2013) Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial. Pharmacogenomics 14:1593–1603
15. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL et al (2013) A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 369:2283–2293
16. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH et al (2013) A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 369:2294–2303
17. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M et al (2012) Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 125:669–676
18. Epstein RS, Moyer TP, Aubert RE, Kane DJ, Xia F et al (2010) Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 55:2804–2812
19. Gage BF, Milligan PE (2005) Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplements. Thromb Res 117:55–59
20. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD et al (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 16:101–110
21. Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP et al (2007) The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med 167:229
22. Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G et al (2013) A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med 369:2304–2312
23. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269
24. Gage B, Eby C, Johnson J, Deych E, Rieder M et al (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84:326–331
25. Ageno W, Johnson J, Nowacki B, Turpie AG (2000) A computer generated induction system for hospitalized patients starting on oral anticoagulant therapy. Thromb Haemost 83:849–852
26. D’Andrea G, D’Ambrosio RL, Di Perna P, Chetta M, Santacroce R et al (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105:645–649
27. Klein T, Altman R, Eriksson N, Gage B, Kimmel S et al (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360:753–764
28. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I et al (2004) Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenet Genomics 14:539–547
29. Huang S-W, Chen H-S, Wang X-Q, Huang L, Xu D-L et al (2009) Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics 19:226–234